Current Treatment Options for Pancreatic Carcinoma

被引：0
作者：
Emily Castellanos
Jordan Berlin
Dana Backlund Cardin
机构：
[1] Vanderbilt University Medical Center,Department of Medicine
[2] Vanderbilt-Ingram Cancer Center,Division of Hematology and Oncology
来源：
Current Oncology Reports | 2011年 / 13卷
关键词：
Pancreatic cancer; CA 19–9; Adjuvant therapy; Chemotherapy; Gemcitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Pancreas cancer is a significant cause of cancer mortality; therefore, the development of early diagnostic strategies and effective treatment is essential. Improvements in imaging technology, as well as use of biomarkers such as CA 19–9, are changing the way that pancreas cancer is diagnosed and staged. Although progress in treatment for pancreas cancer has been incremental, development of combination therapies involving both chemotherapeutic and biologic agents is ongoing. This article reviews current strategies in the diagnosis and treatment of resectable and advanced pancreas cancer.
引用
收藏
页码：195 / 205
页数：10
相关论文
共 180 条
[1]  
Jemal A(2009)Cancer statistics, 2009 CA Cancer J Clin 59 225-49
[2]  
Siegel R(2000)Preoperative evaluation of pancreatic masses with positron emission tomography using 18 F-fluorodeoxyglucose: diagnostic limitations World J Surg 24 1121-9
[3]  
Ward E(2010)Impact of 18-fluorodeoxyglucose positron emission tomography on the management of pancreatic cancer J Gastrointest Surg 14 1151-8
[4]  
Hao Y(2008)18 F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients J Gastrointestin Liver Dis 17 173-8
[5]  
Xu J(2009)A prospective diagnostic accuracy study of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer Ann Surg 250 957-63
[6]  
Thun MJ(1981)Specific antigen in serum of patients with colon carcinoma Science 212 53-5
[7]  
Sendler A(2006)Prognostic and therapeutic significance of carbohydrate antigen 19–9 as tumor marker in patients with pancreatic cancer Oncology 70 255-64
[8]  
Avril N(2006)Cancer antigens 19–9 and 125 in the differential diagnosis of pancreatic mass lesions Arch Surg 141 968-73
[9]  
Helmberger H(1999)Role of tumour markers, cytogenetics Ann Oncol 10 145-9
[10]  
Izuishi K(2006)Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma J Clin Oncol 24 2897-902
12345678910